{"id":"https://openalex.org/W2118894601","doi":null,"title":"Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.","display_name":"Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.","publication_year":2006,"publication_date":"2006-04-01","ids":{"openalex":"https://openalex.org/W2118894601","mag":"2118894601","pmid":"https://pubmed.ncbi.nlm.nih.gov/16736978"},"language":"en","primary_location":{"id":"pmid:16736978","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16736978","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045441776","display_name":"Heinz\u2010Josef Lenz","orcid":"https://orcid.org/0000-0003-2178-9568","observed_orcids":["https://orcid.org/0000-0003-2178-9568"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I4210117038","display_name":"USC Norris Comprehensive Cancer Center","ror":"https://ror.org/01nmyfr60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800154431","https://openalex.org/I4210117038"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Heinz-Josef Lenz","raw_affiliation_strings":["Cancer Genetics, USC/Norris Comprehensive Cancer Center, USC Keck School of Medicine, Los Angeles, California 90033, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Genetics, USC/Norris Comprehensive Cancer Center, USC Keck School of Medicine, Los Angeles, California 90033, USA","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I4210117038"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5045441776"],"corresponding_institution_ids":["https://openalex.org/I1174212","https://openalex.org/I4210117038"],"apc_list":null,"apc_paid":null,"fwci":4.1149,"has_fulltext":false,"cited_by_count":89,"citation_normalized_percentile":{"value":0.94310804,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"20","issue":"5 Suppl 2","first_page":"5","last_page":"13"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.017000000923871994,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor","display_name":"epidermal growth factor receptor","score":0.9279999732971191},{"id":"https://openalex.org/keywords/anti-egfr-therapy","display_name":"anti-EGFR therapy","score":0.7739999890327454},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9879999756813049},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8080000281333923},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.656000018119812},{"id":"https://openalex.org/keywords/acne-like-rash","display_name":"acne-like rash","score":0.7279999852180481},{"id":"https://openalex.org/keywords/interstitial-lung-disease","display_name":"interstitial lung disease","score":0.7229999899864197},{"id":"https://openalex.org/keywords/hypomagnesemia","display_name":"hypomagnesemia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.8389999866485596},{"id":"https://openalex.org/keywords/keratinocyte-proliferation","display_name":"keratinocyte proliferation","score":0.6779999732971191}],"concepts":[{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.8023958802223206},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.793438732624054},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.6950809955596924},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6359047889709473},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5378339290618896},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.507199764251709},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4941461384296417},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.45634540915489197},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.41966235637664795},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3572961688041687},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31739920377731323},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.309087872505188},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.2502426505088806},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.1931130290031433},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.13281327486038208}],"mesh":[{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D017486","descriptor_name":"Acneiform Eruptions","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D017563","descriptor_name":"Lung Diseases, Interstitial","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:16736978","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16736978","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},{"id":"mag:2118894601","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16736978","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W73046920","https://openalex.org/W181130881","https://openalex.org/W1931708823","https://openalex.org/W1972119499","https://openalex.org/W1973060721","https://openalex.org/W2011642803","https://openalex.org/W2046882295","https://openalex.org/W2049484790","https://openalex.org/W2061477629","https://openalex.org/W2067376187","https://openalex.org/W2080414061","https://openalex.org/W2097584581","https://openalex.org/W2103384680","https://openalex.org/W2114291028","https://openalex.org/W2117941094","https://openalex.org/W2120718661","https://openalex.org/W2121306031","https://openalex.org/W2124495521","https://openalex.org/W2135836172","https://openalex.org/W2142564546","https://openalex.org/W2142661339","https://openalex.org/W2168377135","https://openalex.org/W2169332099","https://openalex.org/W2171685800"],"related_works":["https://openalex.org/W2381661869","https://openalex.org/W2066715163","https://openalex.org/W1998085563","https://openalex.org/W7005580078","https://openalex.org/W2074142082","https://openalex.org/W2460495142","https://openalex.org/W2994223912","https://openalex.org/W2396195335","https://openalex.org/W2078134764","https://openalex.org/W1930879179"],"abstract_inverted_index":{"Overexpression":[0],"of":[1,20,55,70,127],"the":[2,24,28,36,52,56,73,83,107,134,187],"epidermal":[3],"growth":[4],"factor":[5],"receptor":[6],"(EGFR)":[7],"is":[8,44,136,161],"correlated":[9],"with":[10,79,99,172,178,197,200],"poor":[11],"prognosis":[12],"in":[13,176,186],"many":[14],"human":[15],"cancers.":[16],"Two":[17],"main":[18],"classes":[19],"anticancer":[21],"agents":[22,71,89,101],"affect":[23],"EGFR:":[25],"those":[26,33,77],"targeting":[27,72],"extracellular":[29],"ligand-binding":[30,53],"domain":[31,54],"and":[32,61,109,118,122],"that":[34,50,168],"block":[35],"intracellular":[37],"tyrosine":[38],"kinase":[39],"(TK)":[40],"domain.":[41],"Cetuximab":[42],"(Erbitux)":[43],"a":[45,150,162],"mouse/human":[46],"chimeric":[47],"monoclonal":[48,202],"antibody":[49],"targets":[51],"EGFR,":[57],"whereas":[58],"erlotinib":[59],"(Tarceva)":[60],"gefitinib":[62],"(Iressa)":[63],"are":[64,94,194],"small-molecule":[65],"TK":[66],"inhibitors.":[67],"Common":[68],"toxicities":[69],"EGFR":[74,184],"differ":[75],"from":[76],"associated":[78],"traditional":[80],"chemotherapy.":[81],"Given":[82],"common":[84],"pathway":[85],"through":[86],"which":[87],"these":[88,100],"work,":[90],"some":[91],"adverse":[92,143],"events":[93,144],"similar.":[95],"Many":[96],"patients":[97],"treated":[98],"develop":[102],"an":[103],"acne-like":[104],"rash":[105],"on":[106],"face":[108],"upper":[110],"body,":[111],"most":[112],"likely":[113],"related":[114,148,182],"to":[115,139,146,149,183],"keratinocyte":[116],"alterations":[117],"hair":[119],"follicle":[120],"proliferation":[121],"maturation.":[123],"Although":[124],"clinical":[125],"manifestation":[126],"this":[128],"reaction":[129,167],"closely":[130],"resembles":[131],"acne":[132],"vulgaris,":[133],"histology":[135],"more":[137],"similar":[138],"infectious":[140],"folliculitis.":[141],"Other":[142],"appear":[145],"be":[147,181],"drug":[151],"class":[152],"or":[153,190],"individual":[154],"agent.":[155],"For":[156],"example,":[157],"interstitial":[158],"lung":[159],"disease":[160],"rare":[163],"but":[164],"potentially":[165],"fatal":[166],"has":[169],"been":[170],"reported":[171,175],"gefitinib.":[173],"Hypomagnesemia":[174],"association":[177],"cetuximab":[179],"may":[180],"blockade":[185],"kidney.":[188],"Anaphylactic":[189],"anaphylactoid":[191],"infusion":[192],"reactions":[193],"also":[195],"seen":[196],"cetuximab,":[198],"as":[199],"other":[201],"antibodies.":[203]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":11},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}